2/4
10:15 am
bioa
BioAge Labs (NASDAQ:BIOA) was given a new $23.00 price target on by analysts at Morgan Stanley.
Low
Report
BioAge Labs (NASDAQ:BIOA) was given a new $23.00 price target on by analysts at Morgan Stanley.
2/3
03:37 am
bioa
1/29
06:16 am
bioa
BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/27
07:01 am
bioa
BioAge Labs (NASDAQ:BIOA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Low
Report
BioAge Labs (NASDAQ:BIOA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/26
04:13 pm
bioa
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
Medium
Report
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
1/26
03:07 am
bioa
Medium
Report
1/21
10:30 pm
bioa
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
Medium
Report
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
1/20
04:18 pm
bioa
BioAge Labs plans up to $75M public stock offering; shares down [Seeking Alpha]
Low
Report
BioAge Labs plans up to $75M public stock offering; shares down [Seeking Alpha]
1/20
04:01 pm
bioa
BioAge Announces Proposed Public Offering
Low
Report
BioAge Announces Proposed Public Offering
1/20
09:00 am
bioa
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
Medium
Report
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
1/18
01:00 am
bioa
1/12
09:00 am
bioa
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
High
Report
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
1/10
01:07 am
bioa
High
Report
1/6
06:22 am
bioa
BLA for subcutaneous formulation of Leqembi® accepted in China
High
Report
BLA for subcutaneous formulation of Leqembi® accepted in China
12/13
10:47 am
bioa
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole [Yahoo! Finance]
Medium
Report
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole [Yahoo! Finance]
12/8
06:44 pm
bioa
Leqembi included in China's commercial insurance innovative drug list
Medium
Report
Leqembi included in China's commercial insurance innovative drug list
12/8
06:42 pm
bioa
Leqembi included in China's commercial insurance innovative drug list
Medium
Report
Leqembi included in China's commercial insurance innovative drug list
12/6
01:36 am
bioa
12/6
01:36 am
bioa
12/5
01:54 pm
bioa
BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $12.00 price target on the stock.
Medium
Report
BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $12.00 price target on the stock.
12/4
10:58 am
bioa
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues [Yahoo! Finance]
Low
Report
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues [Yahoo! Finance]
12/4
09:00 am
bioa
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
High
Report
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
12/4
02:18 am
bioa
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
High
Report
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
12/4
02:13 am
bioa
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
High
Report
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
11/25
06:03 pm
bioa
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]